Characteristics Of Negative And Equivocal Cardiac Scintigraphy Scans And Endomyocardial Biopsy Positive Transthyretin Cardiac Amyloidosis

Joban Vaishnav,Vivek Jani,Artrish Jefferson,Bairavi Shankar,Mark Ranek,Daniel Tsottles,Serena Zampino,Mark Halushka,Michael Polydefkis,Kavita Sharma
DOI: https://doi.org/10.1016/j.cardfail.2023.10.252
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Background Current guidelines favor the use of 99mTc-labeled pyrophosphate scintigraphy (PYP) for diagnosis of transthyretin cardiac amyloidosis (ATTR-CA) given its high sensitivity and specificity. However, studies were conducted in a population with high pre-test probability. We sought to identify characteristics of PYP-negative/equivocal (PYP neg/eq) but endomyocardial biopsy (EMBx)-positive ATTR-CA patients to evaluate its diagnostic performance. Methods Patients who underwent PYP scan and EMBx for evaluation of symptomatic ATTR-CA at Johns Hopkins Hospital were included for analysis. PYP grade 0 and 1 scans (and H/C ratio <1.5) were considered negative and equivocal respectively and grade 2 and 3 scans were considered positive. EMBx slides were reviewed for extent (mild, moderate, severe) and pattern (pericellular, nodular, or vascular deposits) of amyloid deposition. Group comparisons were made with a Mann-Whitney test or chi-squared test, where appropriate. Results Of the 39 patients included, 10 (26%) had grade 0 and 2 (5%) of patients had grade 1 PYP scans with a positive EMBx. Compared to PYP-positive (PYP-pos) patients, PYP-neg/eq patients were younger (63±13 vs. 76±8 years, p=0.003) but matched with respect to race (p=0.52) and sex (p=0.21). A higher proportion of hereditary ATTR-CA was observed in PYP-neg/eq vs. PYP-pos patients, with the exception of the V122I mutation (p=0.005). PYP-neg/eq patients were predominantly National Amyloidosis Center stage 1 disease compared to PYP-pos patients (p=0.02) and consequently had higher eGFR (71±13 vs. 55±21 ml/min/1.73 m2, p=0.01) and lower NT-proBNP (641 [231-2152] vs. 2786[718-4563] pg/mL, p=0.03). Twenty-eight patients had EMBx available for pathology review. Of these, PYP-neg/eq patients had a higher proportion of a mild severity (p=0.001) and a lower proportion of a nodular histologic distribution of amyloid protein (17% vs. 44%). We observed no differences between PYP-pos and -neg/eq patients in hemodynamic or echocardiographic measures (Table 1), apart from smaller LV mass in PYP-neg/eq patients (248±111 vs. 310±90 mL, p=0.04). Survival analysis revealed an increased hazard of a combined endpoint of death and heart failure hospitalization (p=0.04) in PYP-pos vs. neg/eq patients. Conclusion In , we find that PYP may under diagnose less severe, though symptomatic, ATTR-CA in younger patients with hereditary disease. Invasive diagnostic modalities may be necessary to appropriately diagnose such patients. Future studies are needed to investigate the yield of PYP scanning in broader patient populations.
cardiac & cardiovascular systems
What problem does this paper attempt to address?